A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS Trial)
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2018, according to ClinicalTrials.gov record.
- 25 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.